Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04945850 · ClinicalTrials.gov registry record
Can COVID-19 Persist in Intraocular Fluid?
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 25
- Enrollment target
NCT04945850 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT04945850 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Several common viruses thrive and persist in intraocular fluid due to ocular immune privilege. Immune privilege is maintained by lack of lymphatic tissue, a strong blood ocular barrier, and regulation of the systemic immune response via immunosuppressive factors such as TGF-B and processes like anterior chamber associated immune deviation. Notable viruses that benefit from ocular immune sequestration include DNA viruses such as Herpes simplex virus, Varicella Zoster, Cytomegalovirus and RNA viruses like Ebola and Rubella.In light of the global 2019 Severe acute respiratory syndrome coronavirus-2 virus (SARS CoV-2 or commonly COVID-19) pandemic, there has been growing interest on COVID-19's long term effects on the ocular system. Ocular symptoms at the time of diagnosis and during illness have been reported previously. The most commonly reported are epiphora, chemosis, and conjunctivitis. Less common were findings of retinal hemorrhages and retinal ischemic changes. Recent literature has demonstrated its presence in ocular fluid such as tears and the aqueous humor, but whether this is sustained for an extended period of time has yet to be determined. Long term effects of covid on the neurological system are being identified - large vessel ischemic strokes, cerebral hemorrhages, cranial nerve palsies, and memory loss in young adults are being reported. The persistence of COVID 19 in the intraocular fluid several months after covid infection has not been studied previously.
Interventions
- PROCEDURE routine care intraocular sx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2022-06-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04945850
The ClinicalTrials.gov registry entry for NCT04945850 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which routine care intraocular sx is the first listed.
NCT04945850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04945850 about?
NCT04945850 is a clinical study titled "Can COVID-19 Persist in Intraocular Fluid?". Several common viruses thrive and persist in intraocular fluid due to ocular immune privilege. Immune privilege is maintained by lack of lymphatic tissue, a strong blood ocular barrier, and regulation of the systemic immune response via immunosuppressive factors such as TGF-B and processes like ante...
What is the current status of trial NCT04945850?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2021-06-16. Estimated completion is 2022-06-16.
What interventions are being tested in trial NCT04945850?
The interventions under investigation include: routine care intraocular sx (PROCEDURE).
Who is sponsoring clinical trial NCT04945850?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.